Biotechnology company Kytopen has launched an early access programme for its gene delivery platform, Flowfect Discover.
The Flowfect Discover platform is designed for engineering cells with better precision and efficiency.
The platform facilitates the rapid and streamlined delivery of complex genetic engineering materials, such as mRNA, RNA and CRISPR to up to 96 samples within minutes.
Kytopen CEO and co-founder Paulo Garcia said: “Our company aims to empower researchers and developers by enabling more cost-effective innovation that solves manufacturing challenges at the discovery stage of cellular therapies.
“The introduction of the Flowfect Discover platform at an earlier development phase will result in reduced development cost and time savings, contributing to improved patient impact.”
Kytopen has designed the programme for strategic placements of the platform at major contract development and manufacturing organisations and translational academic medical centres.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
This approach is anticipated to help in the rapid delivery of genome engineering materials to living medicines.
The programme speeds up the process of discovering drugs, besides streamlining optimisation and removing obstacles to scaling up to biomanufacturing.
Kytopen CTO Bethany Grant said: “By utilising the same singular technology, the Flowfect Discover and Flowfect Tx empower cell therapy researchers and developers to explore new therapies and optimise delivery with confidence before transitioning to large-scale development.
“This approach saves time, reduces costs and has the potential to revolutionise cell therapy production and life-cycle management for the benefit of patients.”
Initially, the Flowfect Discover platform will have a limited rollout in the US.